Single dose of inhaled procaterol has a prolonged effect on exercise performance of patients with COPD.

Abstract

The aim of this study was to examine the prolonged effect of procaterol, a short-acting bronchodilator, on lung function and exercise performance in patients with moderate to severe COPD. A randomized crossover trial was conducted. We recruited 19 patients with COPD aged 71.6+/-5.5 years. Patients were randomly assigned to receive either 20 mug inhaled procaterol followed by no-treatment or no-treatment followed by 20 mug inhaled procaterol separated by a washout period of 3+/-2 days. Lung function and exercise performance, using the incremental shuttle walking test (ISWT), were measured at baseline and 4 hours after receiving each treatment. Baseline forced expiratory volume in 1 second (FEV(1)) was 38.5%+/-17% predicted. There were no significant changes in FEV(1) following inhaled procaterol. However, walking distance increased by 294+/-113 meters at baseline to 331+/-119 meters after inhaled procaterol (p<0.001). These findings support the beneficial effects of inhaled procaterol on exercise performance in the absence of any change in FEV(1) when measured at 4 hours following inhalation in subjects with moderate to severe COPD. The inhaled procaterol may be useful for enhancing the effects of exercise training in patients with COPD.

• Authors: Toshitaka Sukisaki, Hideaki Senjyu, Kazunori Oishi, Naoto Rikitomi, Koya Ariyoshi
• Journal: Physiotherapy theory and practice (Physiother Theory Pract) 2008 Jul-Aug Vol. 24 Issue 4 Pg. 255-63 ISSN: 1532-5040 [Electronic] England
• PMID: 18574751 (Publication Type: Journal Article, Randomized Controlled Trial)

Chemical References

• Bronchodilator Agents
• Procaterol

Topics

• Administration, Inhalation
• Aged
• Bronchodilator Agents (administration & dosage)
• Cross-Over Studies
• Exercise Tolerance (drug effects)
• Female
• Forced Expiratory Volume (drug effects)
• Humans
• Male
• Muscle Fatigue (drug effects)
• Procaterol (administration & dosage)
• Pulmonary Disease, Chronic Obstructive (complications, drug therapy, physiopathology)
• Severity of Illness Index
• Treatment Outcome
• Walking